[ad_1] SUZHOU, China, Dec. 3, 2025 /PRNewswire/ — On December 3, 2025 (local time in Arizona, USA), ImmVira Group (“ImmVira” or the “Company”) announced a poster presentation at the 26th Annual Meeting of the Society […]

[ad_1] SHENZHEN, China, Sept. 15, 2024 /PRNewswire/ — ImmVira announced the latest clinical results for its lead oncolytic virus product, MVR-T3011, via intravesical administration in patients with high-risk BCG-failure non-muscle invasive bladder cancer (NMIBC). The […]